These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 18704197)

  • 1. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.
    Lo Bianco C; Shorter J; Régulier E; Lashuel H; Iwatsubo T; Lindquist S; Aebischer P
    J Clin Invest; 2008 Sep; 118(9):3087-97. PubMed ID: 18704197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metazoan protein disaggregase and amyloid depolymerase system: Hsp110, Hsp70, Hsp40, and small heat shock proteins.
    Torrente MP; Shorter J
    Prion; 2013; 7(6):457-63. PubMed ID: 24401655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system.
    Shorter J
    PLoS One; 2011; 6(10):e26319. PubMed ID: 22022600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones.
    Hinault MP; Cuendet AF; Mattoo RU; Mensi M; Dietler G; Lashuel HA; Goloubinoff P
    J Biol Chem; 2010 Dec; 285(49):38173-82. PubMed ID: 20847048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of hsp104, a protein disaggregase.
    Sweeny EA; DeSantis ME; Shorter J
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21989490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils.
    Gao X; Carroni M; Nussbaum-Krammer C; Mogk A; Nillegoda NB; Szlachcic A; Guilbride DL; Saibil HR; Mayer MP; Bukau B
    Mol Cell; 2015 Sep; 59(5):781-93. PubMed ID: 26300264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applying Hsp104 to protein-misfolding disorders.
    Vashist S; Cushman M; Shorter J
    Biochem Cell Biol; 2010 Feb; 88(1):1-13. PubMed ID: 20130674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dissection of amyloid disaggregation by human HSP70.
    Wentink AS; Nillegoda NB; Feufel J; Ubartaitė G; Schneider CP; De Los Rios P; Hennig J; Barducci A; Bukau B
    Nature; 2020 Nov; 587(7834):483-488. PubMed ID: 33177717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure and function of the molecular chaperone Hsp104 from yeast.
    Grimminger-Marquardt V; Lashuel HA
    Biopolymers; 2010 Mar; 93(3):252-76. PubMed ID: 19768774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.
    Rochet JC; Conway KA; Lansbury PT
    Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuning Hsp104 specificity to selectively detoxify α-synuclein.
    Mack KL; Kim H; Barbieri EM; Lin J; Braganza S; Jackrel ME; DeNizio JE; Yan X; Chuang E; Tariq A; Cupo RR; Castellano LM; Caldwell KA; Caldwell GA; Shorter J
    Mol Cell; 2023 Sep; 83(18):3314-3332.e9. PubMed ID: 37625404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.
    Jackrel ME; DeSantis ME; Martinez BA; Castellano LM; Stewart RM; Caldwell KA; Caldwell GA; Shorter J
    Cell; 2014 Jan; 156(1-2):170-82. PubMed ID: 24439375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
    Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
    J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons.
    Pujols J; Peña-Díaz S; Lázaro DF; Peccati F; Pinheiro F; González D; Carija A; Navarro S; Conde-Giménez M; García J; Guardiola S; Giralt E; Salvatella X; Sancho J; Sodupe M; Outeiro TF; Dalfó E; Ventura S
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10481-10486. PubMed ID: 30249646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp104, Hsp70, and Hsp40: a novel chaperone system that rescues previously aggregated proteins.
    Glover JR; Lindquist S
    Cell; 1998 Jul; 94(1):73-82. PubMed ID: 9674429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.
    Jackrel ME; Shorter J
    Dis Model Mech; 2014 Oct; 7(10):1175-84. PubMed ID: 25062688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions.
    Shorter J; Lindquist S
    EMBO J; 2008 Oct; 27(20):2712-24. PubMed ID: 18833196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.